IRadimed (IRMD) Q2 2026 Earnings Call Transcript

IRadimed reported Q2 2026 revenue of $20.5 million (up 0.5% YoY) with gross margins compressed to 74% from 78% due to manufacturing inefficiencies during the first production ramp of the new 3870 MRI-compatible pump. The company achieved its manufacturing target of 130-135 units and plans to more than double production to over 300 units in Q3. Strong customer demand drove bookings more than double shipments, with 70% of replacements being quad (4-channel) systems at $110,000+ ASP. Management reaffirmed full-year 2026 guidance of $91-96 million revenue and $2.09-2.24 non-GAAP EPS, expecting margin recovery as manufacturing efficiencies improve.